Blood · 2023 · 51 citations · 27 references
MedicineCancer BiologyOncologyInnate ImmunityMolecular OncologySignal TransductionCancer Stem CellsImmune Cell SignalingInnate Immune ActivationInnate Immune ModulationInnate Immune ResponseInnate Immune Signaling PathwaysAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyInnate Immune EffectorsInnate Immune Signaling ModulationKinase InhibitorsMyd88-dependent SignalingMyelodysplastic Syndrome TherapyMyelodysplastic Syndrome Treatment
Dysregulation of innate immune signaling is a hallmark of hematologic malignancies. Recent therapeutic efforts to subvert aberrant innate immune signaling in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have focused on the kinase IRAK4. IRAK4 inhibitors have achieved promising, though moderate, responses in preclinical studies and clinical trials for MDS and AML. The reasons underlying the limited responses to IRAK4 inhibitors remain unknown. In this study, we reveal that inhibiting IRAK4 in leukemic cells elicits functional complementation and compensation by its paralog, IRAK1. Using genetic approaches, we demonstrate that cotargeting IRAK1 and IRAK4 is required to suppress leukemic stem/progenitor cell (LSPC) function and induce differentiation in cell lines and patient-derived cells. Although IRAK1 and IRAK4 are presumed to function primarily downstream of the proximal adapter MyD88, we found that complementary and compensatory IRAK1 and IRAK4 dependencies in MDS/AML occur via noncanonical MyD88-independent pathways. Genomic and proteomic analyses revealed that IRAK1 and IRAK4 preserve the undifferentiated state of MDS/AML LSPCs by coordinating a network of pathways, including ones that converge on the polycomb repressive complex 2 complex and JAK-STAT signaling. To translate these findings, we implemented a structure-based design of a potent and selective dual IRAK1 and IRAK4 inhibitor KME-2780. MDS/AML cell lines and patient-derived samples showed significant suppression of LSPCs in xenograft and in vitro studies when treated with KME-2780 as compared with selective IRAK4 inhibitors. Our results provide a mechanistic basis and rationale for cotargeting IRAK1 and IRAK4 for the treatment of cancers, including MDS/AML.
27
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Yingyao Zhou, Bin Zhou, Lars Pache et al. · Nature Communications · 2019 · 15.6K citations · Full text
Damian Szklarczyk, Katerina Nastou, David Lyon et al. · Nucleic Acids Research · 2020 · 8.6K citations · Full text
Functional genomic landscape of acute myeloid leukaemia
Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly et al. · Nature · 2018 · 1.5K citations · Full text
Directed evolution of APEX2 for electron microscopy and proximity labeling
Stephanie S Lam, Jeffrey D. Martell, Kimberli J. Kamer et al. · Nature Methods · 2014 · 1.4K citations · Full text
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Eun Hee Kim, Janine O. Ilagan, Yang Liang et al. · Cancer Cell · 2015 · 569 citations · Full text